One of the principal reasons to suspend ongoing research on new therapies is their cardiotoxicity. Regulations require that novel, and promising therapeutic molecules shall be subjected to the rigoristic toxicity tests using traditional methods in vitro and referential animal models. Those tests, however, do not reflect the reaction of human organism on drugs fully; also, they do not allow on detection of many potentially cardiotoxic substances. Direct application of drugs onto human cardiomyocytes, on the one hand, limits the use of lab animals; on the other – it creates a unique opportunity to select and test proper medications correcting particular cardiomyocytes defects. Directly-applied drugs are, therefore, the base of personalized medicine.
Moreover, Acellmed is developing a technology of “the heart-on-the chip,” based on the use of miniaturized micro-circulation systems which will allow on investigating the interaction between different heart cell types, and in the future – also of other organs.
In its research, Acellmed uses human peripheral blood cells (leucocytes), which effectively reprograms into iPSC; afterward, with high efficiency differentiates them into heart cells – cardiomyocytes. Hence we create iPSC bank cells from patients suffering from heart diseases (e.g., genetic primary and secondary cardiomyopathy) and healthy individuals.
As a part of current strategic activities related to the development of an innovative offer, Acellmed is focused on the development of a unique solution being an original nanotherapeutic with no analogue product on the world market so far, that would be effective against SARS-CoV-2 infection and inhibition of COVID-19 disease progression. To date, no similar approach has been found for the formula of an antiviral drug dedicated to the SARS-CoV-2 coronavirus. This furmula may prove to be as effective as or superior to mixtures of human or humanized monoclonal antibodies. The drug significantly reduces the mutational variability of human ACE2, while an approach that includes peptides with a sequence identical to fragments of the ACE2 protein provides no future resistance to the drug.
Our offer will enable the scientists and companies researching new drugs, on selecting safer substances, reducing unnecessary costs of preclinical trials; it may accelerate the process of introducing new drugs into the market.